Clinical Characteristics and Prognostic Risk Factors of Patients With Proven Invasive Pulmonary Aspergillosis: A Single-Institution Retrospective Study.

Xiang Tong, Tao Liu, Kexin Jiang, Dongguang Wang, Sitong Liu, Ye Wang, Hong Fan
Author Information
  1. Xiang Tong: Department of Respiratory Medicine and Critical Care Medicine, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, China.
  2. Tao Liu: Department of Respiratory Medicine and Critical Care Medicine, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, China.
  3. Kexin Jiang: Clinical Medicine of Eight-Year Program, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, China.
  4. Dongguang Wang: Department of Respiratory Medicine and Critical Care Medicine, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, China.
  5. Sitong Liu: Department of Respiratory Medicine and Critical Care Medicine, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, China.
  6. Ye Wang: Department of Respiratory Medicine and Critical Care Medicine, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, China.
  7. Hong Fan: Department of Respiratory Medicine and Critical Care Medicine, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, China.

Abstract

The mortality and burden of medical costs associated with invasive pulmonary aspergillosis (IPA) is very high. Currently, the clinical features and prognostic factors of patients with proven IPA are not very clear, especially in the Chinese population. In this retrospective analysis, we aimed to identify the clinical features and prognostic factors of patients with proven IPA. The diagnostic criteria for proven IPA were based on the international consensus of the EORTC/MSG. Data of patients with proven IPA at the West China Hospital of Sichuan University between January 2012 and December 2018 were collected. The optimal cut-off value of continuous variables was determined by Receiver Operating Characteristic curve and maximum Youden's index. Finally, using the Cox regression analysis to identify correlations between the clinical parameters associated with morbidity. A total of 117 patients with proven IPA were included in the study, and 32 (27.4%) patients died during the follow-up period. Compared with the survivor group, elderly, patients with comorbidities, and patients undergoing chemotherapy and the level of inflammatory biomarkers [erythrocyte sedimentation rate, platelet count, interleukin-6, C-reactive protein (CRP)] in the non-survivor group were higher, while the albumin level was lower ( = 0.018). The imaging features were consolidation, nodules, cavities, pleural effusion, ground-glass shadows, and halo signs in order. Overall, 41.0% patients had mixed imaging features. The results suggested the most appropriate cut-off value of age and CRP were 60 years and 14.1 mg/L, respectively. The multivariate Cox regression analysis suggested that advanced age (>60 years) [hazard ratio (HR): 10.7, confidence interval (CI): 2.5-44.9, < 0.001), undergoing chemotherapy (HR: 9.5, CI: 2.7-32.9, < 0.001), presence of pleural effusion (HR: 5.74, CI: 1.6-20.8, = 0.008), and increased CRP levels (>14.1 mg/L) (HR: 6.3, CI: 1.2-34.3, = 0.033) were risk factors for all-cause mortality in patients with proven aspergillosis. This study showed that the prognosis of proven IPA is poor, and the age >60 years, undergoing chemotherapy, pleural effusion on CT image, and CRP levels >14.1 mg/L may be as risk factors for mortality in patients with proven IPA. large samples and real-world studies are needed to confirm these results in the future.

Keywords

References

  1. Oncology (Williston Park). 2001 Aug;15(8):1035-9; discussion 1040, 1042-4, 1047 [PMID: 11548975]
  2. Infect Drug Resist. 2020 Oct 12;13:3525-3534 [PMID: 33116671]
  3. Clin Infect Dis. 2008 Nov 1;47(9):1176-84 [PMID: 18808352]
  4. J Thorac Dis. 2019 Feb;11(2):465-476 [PMID: 30962990]
  5. J Infect Dis. 2010 Nov 1;202(9):1454-62 [PMID: 20879853]
  6. BMC Public Health. 2019 May 17;19(1):591 [PMID: 31101036]
  7. J Clin Diagn Res. 2016 Aug;10(8):DC01-4 [PMID: 27656435]
  8. Clin Microbiol Infect. 2020 Jun;26(6):781.e1-781.e8 [PMID: 31669427]
  9. J Clin Microbiol. 2017 Jul;55(7):2153-2161 [PMID: 28446576]
  10. Clin Geriatr Med. 2007 Aug;23(3):463-79, v [PMID: 17631228]
  11. Clin Infect Dis. 2019 Nov 13;69(11):2037 [PMID: 30982862]
  12. Mycoses. 2019 Aug;62(8):651-658 [PMID: 31066092]
  13. Arch Microbiol. 2020 Jul;202(5):953-965 [PMID: 32016521]
  14. Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38 [PMID: 29544767]
  15. PLoS One. 2017 Oct 19;12(10):e0186422 [PMID: 29049319]
  16. BMC Pulm Med. 2020 Sep 11;20(1):241 [PMID: 32912168]
  17. Semin Respir Crit Care Med. 2020 Feb;41(1):80-98 [PMID: 32000286]
  18. Clin Infect Dis. 2001 Feb 1;32(3):358-66 [PMID: 11170942]
  19. Clin Infect Dis. 2020 Sep 12;71(6):1367-1376 [PMID: 31802125]
  20. Med Mycol. 2017 Jan 1;55(1):69-81 [PMID: 27794529]
  21. BMJ Open Respir Res. 2016 Dec 16;3(1):e000155 [PMID: 28074136]
  22. Front Med. 2018 Feb;12(1):58-75 [PMID: 29380297]
  23. Drugs. 2007;67(11):1567-601 [PMID: 17661528]
  24. Crit Care. 2016 May 10;20(1):139 [PMID: 27160692]
  25. Clin Infect Dis. 2006 Apr 1;42(7):955-63 [PMID: 16511759]
  26. Clin Chest Med. 2009 Jun;30(2):295-306, vii [PMID: 19375636]
  27. J Int Med Res. 2019 Nov;47(11):5680-5688 [PMID: 31566035]
  28. J Fungi (Basel). 2017 Oct 18;3(4): [PMID: 29371573]

Word Cloud

Created with Highcharts 10.0.0patientsIPAprovenfeatures01clinicalfactorsCRPmortalityanalysisundergoingchemotherapy=imagingpleuraleffusionageyearsmg/L9HR:CI:riskassociatedaspergillosisprognosticidentifycut-offvalueCoxregressionstudygrouplevelresultssuggested>60:2<0015levels>143prognosisburdenmedicalcostsinvasivepulmonaryhighCurrentlyclearespeciallyChinesepopulationretrospectiveaimeddiagnosticcriteriabasedinternationalconsensusEORTC/MSGDataWestChinaHospitalSichuanUniversityJanuary2012December2018collectedoptimalcontinuousvariablesdeterminedReceiverOperatingCharacteristiccurvemaximumYouden'sindexFinallyusingcorrelationsparametersmorbiditytotal117included32274%diedfollow-upperiodComparedsurvivorelderlycomorbiditiesinflammatorybiomarkers[erythrocytesedimentationrateplateletcountinterleukin-6C-reactiveprotein]non-survivorhigheralbuminlower018consolidationnodulescavitiesground-glassshadowshalosignsorderOverall410%mixedappropriate6014respectivelymultivariateadvanced[hazardratioHR107confidenceintervalCI5-447-32presence746-208008increased62-34033all-causeshowedpoorCTimagemaylargesamplesreal-worldstudiesneededconfirmfutureClinicalCharacteristicsPrognosticRiskFactorsPatientsProvenInvasivePulmonaryAspergillosis:Single-InstitutionRetrospectiveStudycharacteristicsfactor

Similar Articles

Cited By